Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- PMID: 32272208
- DOI: 10.1016/j.annonc.2020.03.304
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Keywords: Clinical Practice Guidelines; GEP-NENs; GEP-NETs; Pan-NENs; SI-NETs; diagnosis; gastroenteropancreatic neuroendocrine neoplasms; treatment and follow-up.
Conflict of interest statement
Disclosure MP received honoraria for advisory board and presentations from Novartis, IPSEN, Pfizer, Advanced Accelerator Applications and Lexicon, honoraria for presentations for Prime Oncology and research funding from IPSEN and Novartis. MF received honoraria for presentations from Novartis, IPSEN, Advanced Accelerator Applications and Prime Oncology, honoraria for advisory board from Advanced Accelerator Applications and research funding from IPSEN and Novartis. EPK has an employment interest at Cyclotron Rotterdam BV, stock or other interest, patent or intellectual property interest, travel, accommodation and expenses from Advanced Accelerator Applications. AS has received lecture honoraria from Ipsen and honoraria from Advanced Accelerator Applications. AB has received consultation, advisory and paid public speaking from Bayer, Janssen, Astellas and Novartis and research grants from Janssen and Astellas. AP and KÖ have declared no potential conflicts of interest.
Comment in
-
GEP-NET: Knowledge gaps in the recent ESMO Guidelines.Ann Oncol. 2020 Sep;31(9):1260-1261. doi: 10.1016/j.annonc.2020.04.481. Epub 2020 May 14. Ann Oncol. 2020. PMID: 32417221 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical